---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-023064"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:53:20.532887+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics reports Q1 2024 net loss of $11.7M; cash $90.3M; Takeda Phase 3 soticlestat data expected by Sep 2024

## Summary
- Net loss $11.7M ($0.17/share) vs $13.4M ($0.19) in Q1 2023; revenue $148K.
- Cash $90.3M as of Mar 31, 2024; expected to fund operations into H1 2026.
- Takeda completed Phase 3 trials for soticlestat in LGS and Dravet; topline data expected in H1 2024 fiscal year (by Sep 2024).
- OV888 (GV101) Phase 1 MAD complete; no serious AEs; Phase 2 in CCM expected H2 2024.
- Ovid retains 87% interest in soticlestat milestones (up to $660M) and tiered royalties up to 20%.

## SEC filing metadata
- accession: 0001628280-24-023064
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/0001628280-24-023064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/ovid-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-023064
- JSON: https://secwatch.observer/filing/0001628280-24-023064.json
- Plain text: https://secwatch.observer/filing/0001628280-24-023064.txt

## Key facts
- Earnings Releases
  Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: Ovid Therapeutics Inc. (the "Company") issued a press release announcing Business Update, First Quarter 2024 Financial Results.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/0001628280-24-023064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.